t
Iconic Labs PLC announced that 420,168 new Ordinary Shares were admitted to trading on the London Stock Exchange's Main Market on 17 September 2026. Following this admission, the total number of securities in issue for the company is 17,628,165. As at 30 September 2026, the total number of voting rights in Iconic Labs PLC was 17,628,165 Ordinary Shares of £0.0001 each.
| Date | 30 Sept 2026 |
| Time | 07:01:00 |
| Category | Capital structure |
| ID | 6114W |
Iconic Labs PLC
("Iconic" or the "Company")
Total Voting Rights & Admission to Trading
Total Voting Rights
In accordance with the FCA's Disclosure Guidance and Transparency Rules, as at 30 September 2026, the Company's issued share capital consists of 17,628,165 Ordinary Shares of £0.0001, each with one voting right. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 17,628,165.
The above figure of 17,628,165 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Admission to Trading
In accordance with the Financial Conduct Authority's Prospectus Rules, Iconic announces that 420,168 new Ordinary Shares in the Company were admitted to trading on the Main Market of the London Stock Exchange on 17 September 2026.
|
1) |
Name and LEI |
Iconic Labs PLC 213800YCXZV6RSHGGT04 |
|
2) |
Regulated Market |
London Stock Exchange - Main Market |
|
3) |
Name, type and ISIN |
Ordinary Shares of £0.0001 each ISIN: GB00BRBJ3P08 |
|
4) |
Number of further securities issued and admitted |
420,168 |
|
5) |
Total number of securities in issue following admission |
17,628,165 |
|
6) |
Fungibility |
Fully fungible with existing Ordinary Shares |
|
7) |
Dates of Admission |
17 September 2026 |
|
8) |
Prospectus Information |
N/A |
--ENDS--
For any further information or enquiries please contact:
|
|
||||||
|
|
|
||||||
|
|
|